What is the difference between Liraglutide and Pramlintide?

Liraglutide: GLP-1 receptor agonist; slows gastric emptying, increases satiety, reduces glucagon secretion Pramlintide: Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety

Is Liraglutide FDA approved?

Liraglutide is FDA approved (FDA status current as of 2010-01-25). This regulatory status is provided for research and educational context only.

Is Pramlintide FDA approved?

Pramlintide is FDA approved (FDA status current as of 2005-03-16). This regulatory status is provided for research and educational context only.

How is Liraglutide administered in research settings?

In research settings, Liraglutide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is Pramlintide administered in research settings?

In research settings, Pramlintide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Liraglutide vs Pramlintide

Peptide Comparison

Liraglutide vs Pramlintide

Both are Metabolic peptides.

Liraglutide

Victoza

Fat LossFDA ApprovedPrescription

Half-life: 13 hours

52 providers listed

Full Liraglutide profile →

Pramlintide

Symlin

Fat LossFDA ApprovedPrescription

Half-life: ~48 minutes

No providers listed yet

Full Pramlintide profile →

Bottom line

Liraglutide carries stronger published evidence (Meta-analysis, 8 key studies) than Pramlintide (RCT, 3); both are research compounds.

Quick Verdict

Liraglutide

Half-life

13 hours

Pramlintide

Half-life

~48 minutes

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Liraglutide
Less frequent dosing (longer half-life)	Liraglutide
More provider options (52 vs 0)	Liraglutide

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Liraglutide

Pramlintide

Mechanism Family

Metabolic

Half-life

13 hours

~48 minutes

FDA Status

approved

Admin Routes

subcutaneous

Availability

Prescription

Providers

52 listed

None listed

FDA Update

Jan 2010

Mar 2005

Avail. Notes

FDA-approved GLP-1 agonist. Victoza (NDA 022341, Jan 2010) for T2D; Saxenda (NDA 206321, Dec 2014) for weight management. Prescription only. Generic liraglutide available (generic Victoza, Dec 2024; generic Saxenda, Aug 2025).

FDA-approved amylin analog. Brand: Symlin (NDA 021332, Mar 2005). Adjunct to insulin therapy in T1D and T2D. Prescription only. Subcutaneous injection.

Research Evidence

Liraglutide

Meta-analysis · 8 key studies · most recent 2026

Pramlintide

RCT · 3 key studies · most recent 2026

Research Citations

Liraglutide

Meta-analysis2026 · Diabetes Obes Metab

Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measur…

RCT2022 · JAMA

Semaglutide vs liraglutide for weight loss in adults with overweight or obesity

RCT2015 · New England Journal of Medicine

A randomized, controlled trial of 3.0 mg of liraglutide in weight management

Animal2026 · J Anesth

Effects of the GLP-1 receptor agonist liraglutide on bupivacaine-induced sciatic nerve block in a rat model.

+4 more

Pramlintide

RCT2009 · Obesity

Pramlintide combined with metreleptin in obesity: sustained reductions in weight, metabolic markers, and lept…

RCT2007 · American Journal of Physiology: Endocrinology and Metabolism

Pramlintide reduced 24-h caloric intake and increased satiety in obese subjects: a randomized, double-blind,…

In vitro2026 · J Pharm Biomed Anal

In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive do…

About Liraglutide

GLP-1 receptor agonist; slows gastric emptying, increases satiety, reduces glucagon secretion

Research Areas

appetite suppressionweight lossblood sugar regulation

About Pramlintide

Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety

Research Areas

appetite suppressionpostprandial glucose controlweight lossgastric emptying delay

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Liraglutide

Boxed warning

Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Acute pancreatitisPregnancy (discontinue; not for use in pregnancy)Gallbladder disease / cholelithiasisDiabetic retinopathy complications (reported with GLP-1 receptor agonist use)Severe GI disease / gastroparesis / ileus riskHypoglycemia when combined with insulin or sulfonylureasAcute kidney injury secondary to volume depletion

Source: FDA label

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Pramlintide

Reported (Unverified — Pending Clinical Review)

hypoglycemia unawarenessgastroparesis

No established clinical contraindications

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Find Providers

Where to source these peptides

Providers offering

Liraglutide

52 listed

Browse directory →

Providers offering

Pramlintide

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Metabolic Comparisons

Browse all peptides →

Educational research tools — not medical advice.